CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit
Rosen Law Firm issued a solicitation for Capricor Therapeutics investors to serve as lead plaintiff in a securities fraud class action lawsuit. The complaint alleges Capricor made misleading statements regarding statistical analysis changes for its drug Deramiocel and misrepresented the FDA's stance on its Biologics License Application.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.